Measles-hNIS



Product Description

Product Name: Measles-hNIS (High Titer, 0.5 mL)

Catalog Number: OV1001 Lot Number: OV-MA28 Production ID: 2015-01

Shipping conditions: Dry ice

Storage conditions: Store at ≤ -70°C upon receipt, avoid

subjecting to multiple freeze-thaw cycles

Species: Measles
Virus strain: Edmonston

Transgene: Human sodium iodide symporter (hNIS)

Production Cell Line: Hela S3 cells

Storage Media: Sucrose buffer (5% sucrose, 50 mM Tris,

2mM MgCl₂, pH 7.4)

Measles-hNIS is a recombinant of the live attenuated Edmonston strain of measles virus. The human sodium iodide symporter (hNIS) cDNA is inserted as an additional transcription unit downstream of the hemagglutinin (H) gene (see diagram below). The purchased virus is ready for use in pre-clinical studies and cell killing assays.

Genome:



References

Dingli et al. Blood (2004), 103(5): 1641-1646.

Blechacz et al. Hepatology (2006), 44(6): 1465-1477.

Hasegawa et al. Clinical Cancer Research (2006), 12(6) 1868-1875.

Myers et al. Clinical Pharmacological Therapy (2007), 82(6): 700-710.

Msaouel et al. Molecular Therapy (2009), 17(12): 2041-2048.

Li et al. Cancer Gene Therapy (2010), 17(8): 550 - 558.

Penheiter et al. Am Journal of Roentgenology (2010), 195(2): 341-349.

Opyrchal et al. Human Gene Therapy (2012), 23(4): 419-427.

Li et al. Human Gene Therapy (2012), 23(3): 295-301.

Reddi et al. Cancer Gene Therapy (2012), 19(9): 659-665.

Penheiter et al. Journal of Gene Medicine (2013), 14(9-10): 590-597.

Hutzen et al. BMC Cancer (2012), 12: 508.

Touchefeu et al. Radiotherapy and Oncology (2013), 108(1): 24-31.

Liu et al. Genecology and Oncology (2014), 132(1): 194-202.

Domingo-Musibay et al. Cancer Gene Therapy (2014), 21(11): 483-490.

Galanis et al. Cancer Research (2015), 75(1): 22-30.


Deyle et al. Gene (2015), 565(1): 140-145.

Certificate of Analysis

Test description	Result
Titer (on Vero)	6.9 x108 TCID ₅₀ units/mL
Sterility	Pass QC
Cytopathic Effect	Pass QC
Endotoxin Test	Pass QC
¹²⁵ l Uptake	Pass QC

NIS Expression:

Confirmation of hNIS activity in Measles-hNIS-infected cells performed by Dingli et al. (see reference).



¹²⁵I uptake: human primary myeloma cells were infected (MOI of 2) with the indicated measles viruses and 72 hours later uptake of ¹²⁵I was assayed in the presence or absence of KCIO₄, a specific inhibitor of NIS-mediated ¹²⁵I uptake.

Ref: Dingli et al. Blood (2004), 103(5): 1641-1646. Figure 1E.

Quality Control by: MT Quality Assurance by: LS Effective Date: 20-Nov-2017

Measles-hNIS



Legal Disclaimers

This warranty limits our liability to replacement of this product. No other warranties of any kind, express or implied, including, without limitation, implied warranties of merchantability or fitness for a particular purpose, are provided by Imanis Life Sciences. Imanis Life Sciences shall have no liability for any direct, indirect, consequential, or incidental damages arising out of the use, the results of use, or the inability to use this product.

In no event shall Imanis Life Sciences be liable for any use by Recipient of the Material or for any loss, claim, damage, or liability, of any kind or nature, that may arise from or in connection with the recipient's use, handling, storage, or disposal of the Material, except as such claims, demands, costs, or judgments may arise from Imanis Life Sciences' gross negligence or willful misconduct. Recipient assumes responsibility for, and agrees to indemnify and hold harmless Imanis Life Sciences and Imanis' trustees, officers, agents, and employees from any liability, loss, or damage they may suffer as a result of any claims, demands, costs, or judgments against them arising out of the use, handling, storage, or disposal of the Material by Recipient, except as such claims, demands, costs, or judgments may arise from Imanis Life Sciences' gross negligence or willful misconduct.

For research use only. This certificate is a declaration of analysis at the time of manufacture

PURCHASER NOTIFICATION

LIMITED LICENSE NOTICE - RESEARCH USE ONLY

BY SUBMITTING A SALES ORDER AND OPENING THE PACKAGING OF ORIGINAL MATERIAL, RECIPIENT AGREES TO BE BOUND TO THE TERMS OF THE MATERIAL TRANSFER AGREEMENT ENCLOSED WITH THE PRODUCT. IF RECIPIENT DOES NOT AGREE TO THESE TERMS, DO NOT OPEN THE PACKAGING ON THE ORIGINAL MATERIAL.

- 1. Imanis Life Sciences has exclusive licenses to sell recombinant measles and Vesicular stomatitis viruses for research use. The sale, licensee, lease, export, transfer or other distribution of the Material to entity not party to this MTA for financial gain or other commercial purposes and/or the use of the Material to provide a service to a person or entity not party to this MTA for financial gain; or to produce or manufacture for general sale or products for use in the manufacture of products ultimately intended for general sale is STRICTLY PROHIBITED.
- 2. Limited Use of Material. Recipient may use the Original Material and Progeny only under the direction of Recipient's Scientist for the Research, subject to all of the restrictions set forth herein. No person authorized to use the Material shall be allowed to take or send the Original Material or any Progeny to any location other than the Recipient Scientist's Address, even within Recipient's organization, without Imanis Life Sciences' written consent.
- 3. Limited Rights Granted. All Material is and remains the property of Imanis. Legal title to the Material shall be unaffected by this Agreement or the transfer made hereunder, and nothing in the Agreement grants Recipient any rights under any patents nor any rights to use the Material or any Modifications or process(es) derived from or with the Material for profit-making or Commercial Purposes. Nothing in this Agreement shall alter any rights the U.S. Government may have with respect to the Material.
- 4. Not for human or veterinary use. The Material is for research use only and NOT TO BE USED IN HUMANS OR VETERINARY ANIMALS (including for diagnostic purposes). All research involving the Material (including but not limited to research involving the use of animals and recombinant DNA) and disposal of the Material shall be conducted in accordance with all federal, state, local, import/export and other laws, regulations, and ordinances governing such research including applicable NIH guidelines. Recipient will be solely responsible to obtain any necessary governmental permits or approvals to receive and handle the Material.
- 5. Disclaimers. Any Material delivered pursuant to this Agreement is understood to be experimental in nature, and IMANIS LIFE SCIENCES MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS.